Mateon Announces Collaboration with US Oncology Research to Participate in Phase 2/3 FOCUS Study
September 26 2016 - 8:00AM
Mateon Therapeutics, Inc. (Nasdaq:MATN), a biopharmaceutical
company developing vascular disrupting agents (VDAs) for the
treatment of orphan oncology indications, today announced a
collaboration under which sites affiliated with US Oncology
Research will participate in the FOCUS Study, Mateon’s recently
initiated phase 2/3 clinical trial in platinum-resistant ovarian
cancer.
“We are pleased to work with US Oncology Research, an
outstanding organization that has had tremendous success in
oncology-related clinical trials,” stated William D. Schwieterman,
M.D., President and Chief Executive Officer of Mateon. “US Oncology
Research is selective regarding the studies in which it
participates. So we are pleased they recognize the importance of
developing CA4P for women with platinum-resistant ovarian
cancer.”
US Oncology Research is a premier organization in the United
States dedicated to bringing physicians, clinics and patients
together for innovative cancer research in the community setting.
One of the largest community-based oncology research programs in
the U.S., US Oncology Research has nearly 150 affiliated locations
as well as more than 900 affiliated investigators. The organization
has played a role in the development of more than 60 FDA-approved
cancer therapies, which represents about one-third of all cancer
therapies approved by the FDA to date, and manages about 300 active
clinical trials at any given time.
“Inhibition of tumor-related angiogenesis provides an important
therapeutic option for women with recurrent ovarian cancer,” stated
Michael A. Bookman, M.D., Director, Gynecologic Oncology Research,
US Oncology Research. “Strategies to combine Mateon’s CA4P, a novel
vascular disrupting agent, with other agents, including
bevacizumab, appear promising, and we are excited to offer our
patients the opportunity to participate in this high-priority
randomized trial.”
About FOCUSThe FOCUS Study is a randomized, double-blind, 2-arm,
parallel-group, phase 2/3 study to evaluate the efficacy and safety
of physician’s choice chemotherapy (PCC) plus bevacizumab and CA4P
versus PCC plus bevacizumab in patients with platinum-resistant
ovarian cancer. The primary endpoint of the FOCUS Study is
progression free survival (PFS). The Study will also evaluate
CA4P's effect on objective response rate (ORR), overall survival
(OS) and other parameters. For additional information on the FOCUS
Study, please visit www.clinicaltrials.gov, study identifier
NCT02641639.
About US Oncology ResearchSupported by McKesson Specialty Health
and The US Oncology Network, US Oncology Research draws from a
network of experienced investigators and dedicated clinical staff
who specialize in oncology clinical trials. US Oncology Research
serves approximately 60 research sites and nearly 150 locations
managing about 300 active trials at any given time. Physicians in
the research network have enrolled approximately 63,500 patients in
more than 1,500 trials since inception in 1992 and have played a
role in more than 60 FDA-approved cancer therapies, about one-third
of all cancer therapies approved by the FDA to date. For more
information visit www.usoncology.com/oncologists. To find a US
Oncology Research trial or affiliated practice, visit
www.usoncology.com/patients/find-clinical-trial.
About MateonMateon Therapeutics, Inc. is a biopharmaceutical
company seeking to realize the full potential of vascular targeted
therapy (VTT) in oncology. VTT includes vascular disrupting agents
(VDAs) such as the investigational drugs that Mateon is developing,
and anti-angiogenic agents (AAs), a number of which are
FDA-approved and widely used in cancer treatment. These two
approaches have distinct yet complementary mechanisms of
action.
At Mateon, we believe that we can significantly improve cancer
therapy by employing these two complementary approaches
simultaneously. When utilized this way, VDAs obstruct existing
blood vessels in the tumor leading to significant central tumor
cell death while AAs prevent the formation of new tumor blood
vessels.
Mateon is committed to leveraging our intellectual property and
the product development expertise of our highly skilled management
team to enable VTT to realize its true potential and to bring
much-needed new therapies to cancer patients worldwide.
Safe Harbor StatementThis news release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Any or all of the forward-looking statements in
this press release, which include the timing of advancement,
outcomes, data and regulatory guidance relative to our clinical
programs and achievement of our business and financing objectives
may turn out to be wrong. Forward-looking statements can be
affected by inaccurate assumptions Mateon might make or by known or
unknown risks and uncertainties, including, but not limited to, the
inherent risks of drug development, manufacturing and regulatory
review, and the availability of additional financing to pursue and
continue development of our programs. Additional information
concerning factors that could cause actual results to materially
differ from those in the forward-looking statements is contained in
Mateon's reports to the Securities and Exchange Commission,
including Mateon's reports on Form 10-K, 10-Q and 8-K.
However, Mateon undertakes no obligation to publicly update
forward-looking statements, whether because of new information,
future events or otherwise. Please refer to our Annual Report on
Form 10-K for the fiscal year ended December 31, 2015.
CONTACTS
Investors:
ir@mateon.com
650-635-7000
Media:
JPA Health Communications
Nic DiBella
nic@jpa.com
617-945-5183